After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours.
Stocks Info
Verona Pharma Plc ADR is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. The current market capitalization of Verona Pharma Plc ADR is $7.16B. A total of 2.11 million shares were traded on the day, compared to an average of 1.38M shares.
In the most recent transaction, Hahn Mark W sold 204,864 shares of VRNA for 9.33 per share on May 29 ’25. After the transaction, the Chief Financial Officer now owns 12,678,992 company shares. In a previous transaction on May 28 ’25, Hahn Mark W sold 162,704 shares at 9.30 per share. VRNA shares that Chief Financial Officer owns now total 12,883,856.
Among the insiders who sold shares, Hahn Mark W disposed of 32,432 shares on May 27 ’25 at a per-share price of $9.53. This resulted in the Chief Financial Officer holding 13,046,560 shares of VRNA after the transaction. In another insider transaction, ZACCARDELLI DAVID sold 208,696 shares at $9.33 per share on May 29 ’25. Company shares held by the President and CEO now total 13,590,168.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. In terms of 52-week highs and lows, VRNA has a high of $81.73 and a low of $11.45.
As of this writing, VRNA has an earnings estimate of $0.39 per share for the current quarter. EPS was calculated based on a consensus of 1.0 estimates, with a high estimate of $0.39 per share and a lower estimate of $0.39.
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. VRNA’s latest balance sheet shows that the firm has $148.38M in Cash & Short Term Investments as of fiscal 2021. There were $5.81M in debt and $33.42M in liabilities at the time. Its Book Value Per Share was $2.66, while its Total Shareholder’s Equity was $148.00M.
Analysts Opinion
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for VRNA is Buy with a score of 5.00.
